Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Hidehisa Saeki, Kanako Ishii, Avani Joshi, Arielle G. Bensimon, Hongbo Yang & Isao Kawaguchi. (2022) An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. Journal of Dermatological Treatment 33:1, pages 229-239.
Read now
Read now
Atsuyuki Igarashi, Ataru Igarashi, Christopher N. Graham, Isabelle Gilloteau & Yumiko Tani. (2019) Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. Journal of Medical Economics 22:1, pages 7-15.
Read now
Read now
Shinichi Imafuku, Ataru Nakano, Hidetoshi Dakeshita, Junlong Li, Keith A. Betts & Annie Guerin. (2018) Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. Journal of Dermatological Treatment 29:1, pages 24-31.
Read now
Read now
Nicole C. Rouse, Michael E. Farhangian, Brooke Wehausen & Steven R. Feldman. (2015) The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 877-884.
Read now
Read now
Articles from other publishers (13)
Robin Guelimi, Sivem Afach, Jean Philippe Régnaux, Thomas Bettuzzi, Guillaume Chaby, Emilie Sbidian, Florian Naudet & Laurence Le Cleach. (2022) Overlapping network meta‐analyses on psoriasis systemic treatments, an overview: quantity does not make quality. British Journal of Dermatology 187:1, pages 29-41.
Crossref
Crossref
Hidetoshi Takahashi, Katsuhiko Satoh, Akiyoshi Takagi & Hajime Iizuka. (2021) Cost‐efficacy and pharmacoeconomics of scalp lesions of psoriatic patients in current Japanese health‐care insurance system. The Journal of Dermatology 48:6, pages 883-885.
Crossref
Crossref
Hidetoshi Takahashi, Katsuhiko Satoh, Akiyoshi Takagi & Hajime Iizuka. (2019) Cost‐efficacy and pharmacoeconomics of psoriatic patients in Japan: Analysis from a single outpatient clinic. The Journal of Dermatology 46:6, pages 478-481.
Crossref
Crossref
Nor Azmaniza Azizam, Aniza IsmailSaperi SulongNorazirah Md Nor. (2019) Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia. International Journal of Health Policy and Management 8:7, pages 394-402.
Crossref
Crossref
Rosarin Sruamsiri, Kosuke Iwasaki, Wentao Tang & Jörg Mahlich. (2018) Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatology 18:1.
Crossref
Crossref
Yoshiya Tanaka, Akiko Mizukami, Akihiro Kobayashi, Chie Ito & Taizo Matsuki. (2018) Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. International Journal of Rheumatic Diseases 21:8, pages 1609-1618.
Crossref
Crossref
Christian Kromer, Daniel Celis, Diana Sonntag & Wiebke K. Peitsch. (2018) Biologicals and small molecules in psoriasis: A systematic review of economic evaluations. PLOS ONE 13:1, pages e0189765.
Crossref
Crossref
Hidetoshi Takahashi, Katsuhiko Satoh, Akiyoshi Takagi & Hajime Iizuka. (2017) Economic burden of psoriatic patients in Japan: Analysis from a single outpatient clinic. The Journal of Dermatology 44:9, pages 1024-1026.
Crossref
Crossref
Mandy Gutknecht, Magdalene Krensel & Matthias Augustin. (2016) Health economic analyses of psoriasis management: a systematic literature search. Archives of Dermatological Research 308:9, pages 601-616.
Crossref
Crossref
Aiko Koga, Ikko Kajihara, Saori Yamada, Katsunari Makino, Asako Ichihara, Jun Aoi, Takamitsu Makino, Satoshi Fukushima, Masatoshi Jinnin & Hironobu Ihn. (2015) Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment. The Journal of Dermatology 43:5, pages 522-525.
Crossref
Crossref
Wei Zhang, Nazrul Islam, Canice Ma & Aslam H. Anis. (2014) Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis. PharmacoEconomics 33:4, pages 327-340.
Crossref
Crossref
Shu-Hui Wang, Ching-Chi Chi & Sindy Hu. (2014) Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. International Journal of Dermatology 53:9, pages 1151-1156.
Crossref
Crossref
William Tausend, Christopher Downing & Stephen Tyring. (2014) Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery 18:3, pages 156-169.
Crossref
Crossref